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Dapagliflozin and renal function 
 
Letter related to: 
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Dear Sir 
We read with interest the recently published review published by Mende entitled 
‘Diabetes and kidney disease: the role of Sodium-Glucose Cotransporter-2 (SGLT-2) 
and SGLT-2 inhibitors in modifying disease outcomes [1]. Of interest, there are 
isolated incidents of a deterioration in renal function associated with the use of SGLT-
2 inhibitors in clinical trials [2, 3]. We agree with Mende and other publications [4] 
providing experimental evidence to support that SGLT-2 inhibitors are 
nephroprotective rather than nephrotoxic.  
We have examined changes in renal function in our routine real-world clinic 
practice database before and during treatment with dapagliflozin. Dapagliflozin is 
recommended by NICE as monotherapy or in combination with other anti-diabetic 
medications including insulin in type 2 diabetes [5]. In our practice, dapagliflozin was 
added to concomitant anti-diabetic medications including insulin and GLP-1 agonists. 
We undertook a prospective audit of patients who had been initiated on dapagliflozin 
and had undergone at least one follow-up visit. A paired t-test was performed to 
examine changes in serum creatinine and estimated glomerular filtration rate (eGFR) 
before and during treatment with dapagliflozin. We identified 148 patients (63% 
male) with a mean age of 57.8 ±9.0 years who had received a mean duration of 
treatment of 15.6 ±8.7 months with dapagliflozin. We observed no significant 
changes in pre and post treatment serum creatinine (76 ±18 vs 77 ±21μmol/L, 
P=0.509) and eGFR (92 ±23 vs 92 ±24 mL/min per 1.73 m2, P=0.983). A modest but 
significant reduction in systolic blood pressure (139 ±19 vs 134 ±19mmHg, P=0.002) 
and diastolic blood pressure (79 ±10 vs 77 ±8mmHg, P=0.025) was observed. 
Significant reduction in HbA1c, body weight and doby mass index (BMI) were also 
observed as shown in Table 1. In those individuals with a follow-up of less than 6 
 3 
months (n=23), eGFR decreased from 87 ±20 to 80 ±20 mL/min per 1.73 m2, 
P=0.02). 
In conclusion, no significant change in renal function was observed in our 
cohort (n=148), who had been treated with dapagliflozin for a mean duration of 15.6 
months. Our finding supported the idea that SGLT2 inhibitors are not nephrotoxic. 
Larger studies with long-term follow-up are warranted to confirm the 
nephroprotective effect of SGLT2 inhibitors.  
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Table 1 Mean change in renal function, blood pressure, HbA1c and body weight in patients 
receiving dapagliflozin 
 
Measurement Baseline Follow-up Mean difference 
(95%CI) 
P 
Creatinine (μmol/L) 76 ±18 77 ±21 1 (-2, 4) 0.509 
eGFR (mL/min per 1.73m2) 92 ±23 92 ±24 0 (-3, 3) 0.983 
Weight (kg) 105 ±18 102 ±18 -3 (-4,-2) <0.001 
BMI (kg/m2) 36 ±6 35 ±6 -1 (-1.4,-0.8) <0.001 
SBP (mmHg) 139 ±19 134 ±19 -5 (-8,-2) 0.002 
DBP (mmHg) 79 ±10 77 ±8 -2 (-4, 0.2) 0.025 
HbA1c (mmol/mol) 82 ±18 69 ±13 -13 (-16, -10) <0.001 
Unless indicated otherwise, data are given as the mean ± SD. 
eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; CI: confidence interval. 
 
